[{"address1": "155 Bovet Road", "address2": "Suite 303", "city": "San Mateo", "state": "CA", "zip": "94402", "country": "United States", "phone": "650-561-8600", "website": "https://www.sagimet.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.", "fullTimeEmployees": 8, "companyOfficers": [{"maxAge": 1, "name": "Dr. George W. Kemble Ph.D.", "age": 61, "title": "Executive Chairman of the Board", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 484003, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David A. Happel", "age": 61, "title": "CEO, President & Director", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 836183, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Eduardo Bruno Martins DPhil, M.D., Ph.D.", "age": 60, "title": "Chief Medical Officer", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 649334, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Urs  Greber Ph.D.", "title": "Co-Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lucas  Pelkmans Ph.D.", "title": "Co-Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Thierry  Chauche", "age": 47, "title": "CFO & Principal Accounting Officer", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Elizabeth  Rozek Esq., J.D.", "age": 51, "title": "General Counsel & Chief Compliance Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marie  O'Farrell Ph.D.", "title": "Senior Vice President of Research & Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 10, "compensationRisk": 8, "shareHolderRightsRisk": 10, "overallRisk": 10, "governanceEpochDate": 1719792000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.16, "open": 3.15, "dayLow": 2.92, "dayHigh": 3.19, "regularMarketPreviousClose": 3.16, "regularMarketOpen": 3.15, "regularMarketDayLow": 2.92, "regularMarketDayHigh": 3.19, "forwardPE": -0.75128204, "volume": 601578, "regularMarketVolume": 601578, "averageVolume": 559272, "averageVolume10days": 799200, "averageDailyVolume10Day": 799200, "bid": 2.92, "ask": 2.95, "bidSize": 200, "askSize": 400, "marketCap": 93507728, "fiftyTwoWeekLow": 2.13, "fiftyTwoWeekHigh": 20.71, "priceToSalesTrailing12Months": 46.753864, "fiftyDayAverage": 4.4366, "twoHundredDayAverage": 5.715975, "currency": "USD", "enterpriseValue": -100171312, "floatShares": 15940348, "sharesOutstanding": 30393400, "sharesShort": 2264973, "sharesShortPriorMonth": 2139266, "sharesShortPreviousMonthDate": 1715731200, "dateShortInterest": 1718323200, "sharesPercentSharesOut": 0.071, "heldPercentInsiders": 0.14277, "heldPercentInstitutions": 0.76199996, "shortRatio": 3.75, "shortPercentOfFloat": 0.0849, "bookValue": 5.954, "priceToBook": 0.49210617, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -27918000, "trailingEps": -0.87, "forwardEps": -3.9, "enterpriseToRevenue": -50.086, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "SGMT", "underlyingSymbol": "SGMT", "shortName": "Sagimet Biosciences Inc. - Seri", "longName": "Sagimet Biosciences Inc.", "firstTradeDateEpochUtc": 1689600600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "036364bd-80e6-3704-a7f9-b8281c4b4a2f", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.93, "targetHighPrice": 67.0, "targetLowPrice": 6.0, "targetMeanPrice": 35.8, "targetMedianPrice": 32.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 193704992, "totalCashPerShare": 6.07, "totalDebt": 26000, "quickRatio": 42.95, "currentRatio": 43.124, "totalRevenue": 2000000, "debtToEquity": 0.014, "revenuePerShare": 0.113, "returnOnAssets": -0.18455, "returnOnEquity": -0.26345, "freeCashflow": -15140375, "operatingCashflow": -22890000, "grossMargins": 1.0, "operatingMargins": -16.3715, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-03"}]